PriceTargets.com logo

Marpai - MRAI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 365.12%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.29 As of 12/18/2024 10:46 AM ET
▲ +0.18 (16.22%)

This chart shows the closing price for MRAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Marpai Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRAI

Analyst Price Target is $6.00
▲ +365.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Marpai in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 365.12% upside from the last price of $1.29.

This chart shows the closing price for MRAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Marpai. This rating has held steady since March 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/28/2024Maxim GroupUpgradeHold ➝ Buy$6.00
11/14/2023Maxim GroupReiterated RatingBuy ➝ Hold
8/1/2022Maxim GroupInitiated CoverageBuy$10.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Marpai logo
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.
Read More

Today's Range

Now: $1.29
Low: $1.24
High: $1.29

50 Day Range

MA: $1.04
Low: $0.48
High: $1.64

52 Week Range

Now: $1.29
Low: $0.40
High: $2.97

Volume

244 shs

Average Volume

259,916 shs

Market Capitalization

$17.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Marpai?

The following Wall Street sell-side analysts have issued research reports on Marpai in the last twelve months: Maxim Group.
View the latest analyst ratings for MRAI.

What is the current price target for Marpai?

0 Wall Street analysts have set twelve-month price targets for Marpai in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 365.1%. Maxim Group has the highest price target set, predicting MRAI will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for Marpai in the next year.
View the latest price targets for MRAI.

What is the current consensus analyst rating for Marpai?

Marpai currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRAI will outperform the market and that investors should add to their positions of Marpai.
View the latest ratings for MRAI.

What other companies compete with Marpai?

Other companies that are similar to Marpai include Enzo Biochem, Concord Medical Services, Psychemedics, Oncology Institute and BioRestorative Therapies. Learn More about companies similar to Marpai.

How do I contact Marpai's investor relations team?

The company's listed phone number is 646-303-3483 and its investor relations email address is [email protected]. The official website for Marpai is www.marpaihealth.com. Learn More about contacing Marpai investor relations.